This CPB has been updated to: (i) for Aetna commerical plans, change "Least Cost Medically Necessary Brands" subheading to "Brand Selection for Medically Necessary Indications", (ii) update nomenclature for "Brand Selection for Medically Necessary Indications" to reflect Aetna commercial plan language, (iii) for Aetna commercial plans, to add a note to the  'Brand Selection for Medically Necessary Indications' paragraph that "For psoriasis, this policy applies to all adult members requesting treatment with a targeted immune modulator. For all other indications, this policy applies to adult members who are new to treatment with a targeted immune modulator for the first time.", (iv) to designate, for Aetna commercial plans, Cimzia as a nonpreferred targeted immune modulator for plaque psoriasis and psoriatic arthritis, (v) for Aetna commercial plans, requirements for a trial of lower cost targeted immune modulators are waived for persons requesting Cimzia who are pregnant or breastfeeding, (vi) to add a note to the  'Dosing and Administration' section stating "Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines", and (vii) reorganize the policy format and subheader locations.